INTRODUCTION: Alopecia areata (AA) is associated with thyroid dysfunction and abnormal levels of thyroglobulin and thyroid peroxidase autoantibodies. One study detected high prevalence of thyrotropin receptor antibodies (TRAbs) in AA patients. Our aim was to investigate the prevalence of TRAb levels in AA patients and to assess their association with thyroid hormones, other thyroid antibodies, AA severity, and other epidemiological variables. METHODS: In this observational study, 139 patients (97 females, 42 males), aged 12 and above, with newly presenting, relapsing, or treatment-resistant AA were included. Medical histories were reviewed, alopecia severity was assessed using the Severity of Alopecia Tool (SALT), and blood tests measured thyroid hormones and autoantibodies. RESULTS: The prevalence of TRAb was significantly higher in AA patients (23.6%) compared to the general population (1-2%) (p < 0.001). Elevated TRAb titers did not correlate with diagnosed thyroid dysfunction or treatment, abnormal thyroid function tests and autoantibodies, AA severity, duration, and onset. Male patients exhibited a significantly higher prevalence of abnormal TRAb titers compared to females (75.0% vs. 21.3%, p = 0.002). CONCLUSION: A significant proportion of AA patients presented with elevated TRAb levels, independent of thyroid hormone titers, other thyroid autoantibodies, or SALT score. Prevalence of abnormal TRAb levels was higher in males.

Department of Biostatistics National Institute of Public Health and Department of Epidemiology and Biostatistics 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Dermatovenerology 3rd Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady Prague Czech Republic

Zobrazit více v PubMed

Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403. PubMed PMC

Stefanis AJ, Arenberger P, Arenbergerova M, Gkalpakiotis S. Alopecia barbae severity score: a novel scoring system to estimate the extent of beard loss and success of treatment. Br J Dermatol. 2021;185(4):847–9. PubMed

Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):923–31. PubMed

Noso S, Park C, Babaya N, Hiromine Y, Harada T, Ito H, et al. . Organ specificity in autoimmune diseases: thyroid and islet autoimmunity in alopecia areata. J Clin Endocrinol Metab. 2015;100(5):1976–83. PubMed

Senna M, Ko J, Tosti A, Edson-Heredia E, Fenske DC, Ellinwood AK, et al. . Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims. Adv Ther. 2021;38(9):4646–58. PubMed PMC

Park SM, Oh YJ, Lew BL, Sim WY. The association among thyroid dysfunction, thyroid autoimmunity, and clinical features of alopecia areata: a retrospective study. J Am Acad Dermatol. 2019;81(2):602–5. PubMed

Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(2):466–77.e16. PubMed

Davies TF, Latif R. Editorial: TSH receptor and autoimmunity. Front Endocrinol. 2019;10:19. PubMed PMC

Mooij CF, Cheetham TD, Verburg FA, Eckstein A, Pearce SH, Léger J, et al. . 2022 European thyroid association guideline for the management of pediatric Graves’ disease. Eur Thyroid J. 2022;11(1):e210073. PubMed PMC

Orgiazzi J. Anti-TSH receptor antibodies in clinical practice. Endocrinol Metab Clin North Am. 2000;29(2):339–55. vii. PubMed

Lee S, Lee YB, Kim BJ, Lee WS. Screening of thyroid function and autoantibodies in patients with alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1410–3.e4. PubMed

Popa A, Carsote M, Cretoiu D, Dumitrascu MC, Nistor CE, Sandru F, et al. . Survival prediction in diabetic foot ulcers: a machine learning approach. J Clin Med. 2023;12(18):5816. PubMed PMC

Olsen EA, Roberts J, Sperling L, Tosti A, Shapiro J, McMichael A, et al. . Objective outcome measures: collecting meaningful data on alopecia areata. J Am Acad Dermatol. 2018;79(3):470–8.e3. PubMed PMC

Česká Společnost Klinické Biochemie . Doporučení pro laboratorní diagnostiku funkčních a autoimunních onemocnění štítné žlázy. Klin Biochem Metab. 2011;19(40):14.

Kasumagić-Halilović E. Thyroid autoimmunity in patients with alopecia areata. Acta Dermatovenerol Croat. 2008;16(3):123–5. PubMed

Bin Saif GA. Severe subtype of alopecia areata is highly associated with thyroid autoimmunity. Saudi Med J. 2016;37(6):656–61. PubMed PMC

Gao Y, Huo S, Sun M, Zhang C, Wang J, Gao J, et al. . Evaluation of several immune and inflammatory indicators and their association with alopecia areata. J Cosmet Dermatol. 2022;21(7):2995–3001. PubMed

Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4(3):149–63. PubMed PMC

Vieira IH, Rodrigues D, Paiva I. The mysterious universe of the TSH receptor. Front Endocrinol. 2022;13:944715. PubMed PMC

Bodo E, Kromminga A, Biro T, Borbiro I, Gaspar E, Zmijewski MA, et al. . Human female hair follicles are a direct, nonclassical target for thyroid-stimulating hormone. J Invest Dermatol. 2009;129(5):1126–39. PubMed

Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29(8):703–25. PubMed

Taketomo Y, Noso S, Babaya N, Hiromine Y, Ito H, Kanto K, et al. . Common phenotype and different non-HLA genes in Graves’ disease and alopecia areata. Hum Immunol. 2017;78(2):185–9. PubMed

Hesarghatta Shyamasunder A, Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves’ disease. Clin Endocrinol. 2017;86(5):652–7. PubMed

Lindgren O, Asp P, Sundlöv A, Tennvall J, Shahida B, Planck T, et al. . The effect of radioiodine treatment on TRAb, anti-TPO, and anti-TG in Graves’ disease. Eur Thyroid J. 2019;8(2):64–9. PubMed PMC

Li J, Bai L, Wei F, Wei M, Xiao Y, Yan W, et al. . Effect of addition of thyroxine in the treatment of Graves' disease: a systematic review. Front Endocrinol. 2020;11:560157. PubMed PMC

Nakamura H, Usa T, Motomura M, Ichikawa T, Nakao K, Kawasaki E, et al. . Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest. 2008;31(10):861–5. PubMed

Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol. 2016;74(2):295–302. PubMed

Zhang C, Hong C, Lian X, Wen L, Xu K, Tian Z, et al. . Correlations of thyroid autoantibodies with allergic diseases: a case-control study of 434 Chinese patients. Medicine. 2022;101(30):e29871. PubMed PMC

Unnikrishnan AG, Kumaravel V, Nair V, Rao A, Jayakumar RV, Kumar H, et al. . TSH receptor antibodies in subjects with type 1 diabetes mellitus. Ann N Y Acad Sci. 2006;1079:220–5. PubMed

Koszarny A, Majdan M, Suszek D, Wielosz E, Dryglewska M. Relationship between rheumatoid arthritis activity and antithyroid antibodies. Pol Arch Med Wewn. 2013;123(7–8):394–400. PubMed

Zuhur S, Bilen O, Aggul H, Topçu B, Celikkol A, Elbuken G. The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves’ Hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative Graves’ hyperthyroidism. Endokrynol Pol. 2021;72(1):14–21. PubMed

Suzuki N, Kawaguchi A, Yoshimura Noh J, Yoshimura R, Mikura K, Kinoshita A, et al. . Clinical course of euthyroid subjects with positive TSH receptor antibody: how often does Graves’ disease develop? J Endocr Soc. 2021;5(6):bvab042. PubMed PMC

Calcaterra V, Nappi RE, Regalbuto C, De Silvestri A, Incardona A, Amariti R, et al. . Gender differences at the onset of autoimmune thyroid diseases in children and adolescents. Front Endocrinol. 2020;11:229. PubMed PMC

Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SCL, Franklyn JA. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2000;85(3):1038–42. PubMed

Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347–69. PubMed

Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. . Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675–82. PubMed